144.36
0.99%
1.41
After Hours:
144.36
Illumina Inc stock is traded at $144.36, with a volume of 1.28M.
It is up +0.99% in the last 24 hours and up +1.70% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$142.95
Open:
$144.11
24h Volume:
1.28M
Relative Volume:
0.70
Market Cap:
$22.86B
Revenue:
$4.39B
Net Income/Loss:
$-1.58B
P/E Ratio:
-5.425
EPS:
-26.61
Net Cash Flow:
$546.00M
1W Performance:
+9.63%
1M Performance:
+1.70%
6M Performance:
+35.57%
1Y Performance:
+52.52%
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
144.36 | 22.86B | 4.39B | -1.58B | 546.00M | -26.61 |
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
Aug-28-24 | Upgrade | Argus | Hold → Buy |
Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
Jun-03-24 | Resumed | Jefferies | Hold |
Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
Dec-14-23 | Initiated | Guggenheim | Buy |
Dec-14-23 | Initiated | Stephens | Overweight |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
Sep-28-23 | Initiated | Bernstein | Underperform |
Jul-05-23 | Resumed | JP Morgan | Neutral |
Jan-25-23 | Downgrade | Argus | Buy → Hold |
Jan-05-23 | Initiated | Scotiabank | Sector Perform |
Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
Aug-25-22 | Initiated | Credit Suisse | Neutral |
Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
Jan-18-22 | Upgrade | Stifel | Hold → Buy |
Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
Jan-06-22 | Resumed | Piper Sandler | Overweight |
Oct-15-21 | Resumed | Cowen | Outperform |
Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
Mar-03-21 | Initiated | Barclays | Underweight |
Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
Sep-22-20 | Downgrade | Stifel | Buy → Hold |
Sep-22-20 | Downgrade | UBS | Buy → Neutral |
Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Jan-08-20 | Initiated | Wells Fargo | Underweight |
Jan-07-20 | Initiated | Citigroup | Buy |
Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-15-19 | Initiated | Stifel | Buy |
Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
This Illumina Insider Increased Their Holding In The Last Year - Yahoo Finance
Daiwa Securities Group Inc. Sells 8,783 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Citigroup Inc. Increases Stock Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Life Science Tools Market Generated Opportunities, Future - openPR
Illumina, Inc. (ILMN): Constrained Spending in Pharmaceutical Industry Pressures Shares Despite Strong Niche Position - Yahoo Finance
Early access users rave about Illumina’s new MiSeq i100 Series - Illumina
Loomis Sayles & Co. L P Has $566.34 Million Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2 - Yahoo Finance
Swedbank AB Has $56.84 Million Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 10,455 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina, Inc. (NASDAQ:ILMN) Stake Cut by Pathstone Holdings LLC - MarketBeat
Massachusetts Financial Services Co. MA Raises Stock Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Purchases Shares of 5,441 Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Stocks With Rising Relative Strength: Illumina - MSN
Edgewood Management LLC Sells 19,221 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Jennison Associates LLC Acquires 89,663 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Metagenomics Market Is Booming Worldwide 2024-2031 | Bio-Rad - openPR
United States Non-Invasive Prenatal Testing Market Report 2025-2033: Illumina, Roche, and Natera, which have Established Themselves as Leaders through Robust Research and Development - Yahoo Finance
Bioinformatics Market Size, Trends, Growth, Opportunities - openPR
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Trailblazing study shows early CGP leads to better precision treatments - Illumina
Primecap Management Co. CA Buys 87,599 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Buys 114,466 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina gear up to expand TruSight Oncology portfolio - Medical Device Network
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Myriad Genetics Announces Incorporation of its Proprietary - GlobeNewswire
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 - Yahoo Finance
(ILMN) Trading Report - Stock Traders Daily
Illumina's Moat in Sequencing Remains Narrow - Morningstar
Illumina To Present At Wolfe Research 2024 Healthcare Conference; Webcast At 9:20 AM ET - Nasdaq
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio - Yahoo Finance
Gene Panel Market: Rapid Growth with Strong Future CAGR and Top - openPR
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Victory Capital Management Inc. - MarketBeat
Biological Multiplex Assays Market to Witness Significant - openPR
U.S. STOCKS Merck, Microstrategy, Illumina - XM
Illumina to unveil new tumor profiling assay at AMP - Investing.com
Illumina announces expansion of TruSight Oncology portfolio - Illumina
LMR Partners LLP Takes Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
RNA Sequencing Market Expected to Experience Positive Growth - openPR
NGS Based RNA Sequencing Market 2024 Analysis of Key Trends, - openPR
Digital Genome Market May See a Big Move | Illumina, GE Healthcare, Inscripta - openPR
How two systems integration scientists ensure a smooth workflow on MiSeq i100 - Illumina
Is Illumina, Inc. (ILMN) the Best Immunotherapy Stock to Buy Now? - Yahoo Finance
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Mutual of America Capital Management LLC - MarketBeat
CIBC Asset Management Inc Sells 19,552 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
10 Best Immunotherapy Stocks to Buy Now - Insider Monkey
NGS & Microarray Training - Illumina
Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by Impax Asset Management Group plc - MarketBeat
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):